Addition of Dexmedetomidine to the Anesthesia Regimen Attenuates Pain and Improves Early Recovery After Esophageal Endoscopic Submucosal Dissection: A Randomized Controlled Trial
Xin Luo,Hai-Jun Hou,Pei-Shan Chen,Xin-Lu Chang,Yang Li,Li-Xin An,Fu-Kun Liu,Fu-Shan Xue
DOI: https://doi.org/10.2147/dddt.s475749
IF: 4.3188
2024-10-12
Drug Design Development and Therapy
Abstract:Xin Luo, 1, &ast Hai-Jun Hou, 2, &ast Pei-Shan Chen, 1 Xin-Lu Chang, 1 Yang Li, 1 Li-Xin An, 1 Fu-Kun Liu, 1 Fu-Shan Xue 1, 3 1 Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China; 2 Department of Pain Medicine, Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People's Republic of China; 3 Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Fu-Shan Xue, Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian Province, 350001, People's Republic of China, Tel +86-13911177655, Fax +86-0591-88217841, Email ; Objective: Postoperative pain is a common yet often underestimated complication following esophageal endoscopic submucosal dissection (ESD), with limited strategies for effective management. This prospective, double-blind, randomized controlled trial assessed the effects of adding dexmedetomidine (DEX) to the anesthesia regimen on postoperative pain and early recovery in patients undergoing esophageal ESD. Methods: In total, 60 patients scheduled for elective esophageal ESD under general anesthesia were randomly assigned to the DEX or control group. The DEX group received an intravenous loading dose of DEX at 1 μg/kg for 10 min, followed by a continuous intravenous infusion of 0.6 μg/kg/h, which was stopped 30 min before the end of the procedure. The control group received normal saline as a placebo. The study's primary outcome was the incidence of moderate-to-severe postoperative pain. Secondary outcomes included postoperative pain scores, hemodynamic parameters, the occurrence of postoperative nausea and vomiting (PONV), patient satisfaction, and lengths of stay in the post-anesthesia care unit (PACU) and hospital. Results: The incidence of moderate-to-severe postoperative pain in the DEX group was significantly lower than that in the control group (absolute difference: − 33.4%; OR: 0.250; 95% CI: 0.085– 0.731, P = 0.01). Pain scores at 1 h postoperatively (0.5[2.0] vs 3.0[1.3], P = 0.003) were significantly lower in the DEX group. Additionally, morphine dosage in the PACU (0[0] vs 1.0[2.0] P = 0.004) was significantly reduced in the DEX group compared with the control group. In the DEX group, the incidence and severity of PONV were significantly decreased and the length of PACU stay was shorter than in the control group ( P < 0.01). However, the rates of intraoperative hypotension, tachycardia, and bradycardia were similar between the two groups. Patient satisfaction and length of hospital stay were also comparable. Conclusion: Adding DEX to the anesthesia regimen for esophageal ESD significantly attenuates postoperative pain and improves early recovery outcomes. Keywords: endoscopic submucosal dissection, esophageal neoplasm, dexmedetomidine, postoperative pain, adverse events Endoscopic submucosal dissection (ESD) is a minimally invasive technique used to treat esophageal neoplasms. It is highly valued for its ability to achieve high en-bloc resection rates and minimize local recurrence. 1,2 However, despite these advantages, recent studies have highlighted the frequent complications associated with ESD for early esophageal cancer, such as delayed bleeding, infection, postoperative pain, and stenosis. 3 The ESD-associated complications are often a great concern and can be treated in a timely manner. Postoperative pain, while a significant concern, has often been undervalued and inadequately addressed in both clinical practice and research. 2,4 Only a few studies have focused on postoperative pain in patients undergoing esophageal ESD. For example, only two retrospective studies have reported that the incidence of postoperative chest pain or non-cardiac chest pain (NCCP) after esophageal ESD ranges from 35.7%–49.5%. However, no study has reported effective postoperative analgesia strategies for this procedure. 4,5 Even the Chinese expert consensus on sedation and anesthesia in digestive endoscopy 6 recommends only non-steroidal anti-inflammatory drugs as analgesics for pain control after ESD. Unmanaged postoperative pain not only decreases patient satisfaction but also prolongs hospitalization and increases me -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal